The J&J COVID-19 vaccine: Fit for purpose in our setting

摘要

On 12 April 2021, the US Centers for Disease Control called a halt to the use of the Johnson and Johnson (J&J)’s coronavirus vaccine[1] while reviewing data on the more than 6.8 million doses that had been administered in the USA as of 12 April, that involved 6 reported US cases of a vanishingly rare but severe blood clot, cerebral venous sinus thrombosis (CVST), seen in combination with thrombocytopenia. All 6 cases occurred in women between the ages of 18 and 48 years, and symptoms developed 6 - 13 days after vaccination. To date, the USA has not resumed vaccination with the J&J COVID-19 vaccine, but it is likely that they will do so.